terazosin ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antihypertensive substances, prazosin derivatives 3584 63590-64-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • terazosin
  • terazosin hydrochloride
  • terazosin hydrochloride anhydrous
  • terazosine
  • terazosin hydrochloride hydrate
  • terazosin HCl
induces decreased blood pressure; used in the treatment of benign prostatic hyperplasia
  • Molecular weight: 387.44
  • Formula: C19H25N5O4
  • CLOGP: 2.23
  • LIPINSKI: 0
  • HAC: 9
  • HDO: 1
  • TPSA: 103.04
  • ALOGS: -2.41
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
5 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 24.20 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.86 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 90 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.98 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.10 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.08 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 9 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Aug. 7, 1987 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyperkalaemia 40.60 26.23 22 1581 54181 63433238
Sleep disorder due to a general medical condition 32.31 26.23 12 1591 12176 63475243

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypotension 44.33 15.10 139 8633 221510 34726649
Syncope 36.92 15.10 75 8697 91376 34856783
Dizziness 36.51 15.10 129 8643 218392 34729767
Orthostatic hypotension 33.88 15.10 37 8735 25882 34922277
Distributive shock 32.02 15.10 12 8760 1242 34946917
Asthenia 31.33 15.10 133 8639 245118 34703041
Pulseless electrical activity 29.88 15.10 20 8752 7191 34940968
Heart valve incompetence 26.77 15.10 11 8761 1453 34946706
Bradyarrhythmia 25.55 15.10 12 8760 2179 34945980
Non-cardiogenic pulmonary oedema 23.18 15.10 8 8764 653 34947506
Myasthenic syndrome 20.87 15.10 7 8765 524 34947635
Dysuria 19.85 15.10 29 8743 27123 34921036
Toxicity to various agents 19.77 15.10 13 8759 200349 34747810
Diffuse alveolar damage 19.05 15.10 10 8762 2304 34945855
Myocardial infarction 18.89 15.10 70 8702 121015 34827144
Sinus bradycardia 17.80 15.10 19 8753 12944 34935215
Sopor 17.04 15.10 18 8754 12118 34936041
Coronary artery disease 16.45 15.10 37 8735 48268 34899891
Presyncope 16.37 15.10 22 8750 19037 34929122

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypotension 67.47 15.89 151 8816 440166 79295255
Hyperkalaemia 50.09 15.89 63 8904 114335 79621086
Orthostatic hypotension 38.38 15.89 39 8928 56125 79679296
Bradycardia 34.85 15.89 58 8909 135499 79599922
Asthenia 33.80 15.89 130 8837 511559 79223862
Acute kidney injury 33.52 15.89 131 8836 519273 79216148
Coronary artery disease 33.44 15.89 39 8928 65435 79669986
Distributive shock 32.49 15.89 12 8955 2675 79732746
Pulseless electrical activity 32.22 15.89 20 8947 14140 79721281
Dizziness 31.75 15.89 130 8837 526311 79209110
Syncope 31.33 15.89 65 8902 179384 79556037
Myocardial infarction 30.18 15.89 65 8902 184064 79551357
Bradyarrhythmia 27.45 15.89 12 8955 4134 79731287
Heart valve incompetence 26.69 15.89 11 8956 3280 79732141
Myasthenic syndrome 23.22 15.89 7 8960 835 79734586
Non-cardiogenic pulmonary oedema 23.05 15.89 8 8959 1491 79733930
Diffuse alveolar damage 22.47 15.89 10 8957 3594 79731827
Cerebrovascular accident 22.27 15.89 52 8915 155240 79580181
Blood creatinine increased 21.24 15.89 51 8916 155006 79580415
Dysuria 20.61 15.89 27 8940 50924 79684497
Renal failure 20.29 15.89 59 8908 200909 79534512
Presyncope 20.20 15.89 24 8943 41030 79694391
Cardiovascular disorder 19.10 15.89 16 8951 18009 79717412
Lactic acidosis 16.61 15.89 29 8938 70330 79665091
Gastrointestinal haemorrhage 16.50 15.89 45 8922 147674 79587747
Sinus bradycardia 16.28 15.89 17 8950 25230 79710191
Atrial fibrillation 16.18 15.89 54 8913 197832 79537589
Asthma 15.94 15.89 42 8925 135053 79600368

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC G04CA03 GENITO URINARY SYSTEM AND SEX HORMONES
UROLOGICALS
DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY
Alpha-adrenoreceptor antagonists
FDA MoA N0000000099 Adrenergic alpha-Antagonists
FDA EPC N0000175553 alpha-Adrenergic Blocker
MeSH PA D018663 Adrenergic Agents
MeSH PA D058668 Adrenergic alpha-1 Receptor Antagonists
MeSH PA D000317 Adrenergic alpha-Antagonists
MeSH PA D018674 Adrenergic Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D064804 Urological Agents
CHEBI has role CHEBI:35610 antineoplastic agents
CHEBI has role CHEBI:35674 antihypertensive drugs
CHEBI has role CHEBI:37890 alpha-adrenergic receptor blockaders

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Benign prostatic hyperplasia indication 266569009
Priapism contraindication 6273006 DOID:9286
Orthostatic hypotension contraindication 28651003
Cataract surgery contraindication 110473004
Syncope contraindication 271594007
Intraoperative floppy iris syndrome contraindication 418801006




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.22 Basic
pKa2 0.72 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Alpha-1B adrenergic receptor GPCR ANTAGONIST Ki 9.08 WOMBAT-PK CHEMBL
Alpha-1A adrenergic receptor GPCR ANTAGONIST Ki 8.95 WOMBAT-PK CHEMBL
Alpha-1D adrenergic receptor GPCR ANTAGONIST Ki 9.20 WOMBAT-PK CHEMBL
Alpha-2B adrenergic receptor GPCR Ki 6.93 WOMBAT-PK
Alpha-2C adrenergic receptor GPCR Ki 6.88 WOMBAT-PK
Ribosyldihydronicotinamide dehydrogenase [quinone] Enzyme WOMBAT-PK
Solute carrier family 22 member 1 Transporter IC50 4.63 CHEMBL
Alpha-2A adrenergic receptor GPCR Ki 6.26 WOMBAT-PK
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 4.75 CHEMBL
5-hydroxytryptamine receptor 2A GPCR Ki 5.45 PDSP
Alpha-1B adrenergic receptor GPCR Ki 8.72 CHEMBL
Alpha-1A adrenergic receptor GPCR Ki 9.09 CHEMBL
Alpha-2B adrenergic receptor GPCR Ki 8.11 CHEMBL
Alpha-1D adrenergic receptor GPCR Ki 9 CHEMBL
Alpha-1A adrenergic receptor GPCR Ki 7.59 CHEMBL
Alpha-1B adrenergic receptor GPCR Ki 9.16 CHEMBL

External reference:

IDSource
4019940 VUID
N0000179262 NUI
D00610 KEGG_DRUG
70024-40-7 SECONDARY_CAS_RN
63074-08-8 SECONDARY_CAS_RN
4019435 VANDF
4019940 VANDF
C0076107 UMLSCUI
CHEBI:9445 CHEBI
TZN PDB_CHEM_ID
CHEMBL611 ChEMBL_ID
DB01162 DRUGBANK_ID
CHEMBL3989562 ChEMBL_ID
CHEMBL1256665 ChEMBL_ID
C041226 MESH_SUPPLEMENTAL_RECORD_UI
5401 PUBCHEM_CID
7302 IUPHAR_LIGAND_ID
4843 INN_ID
8L5014XET7 UNII
1299927 RXNORM
31270 MMSL
44696 MMSL
5546 MMSL
d00386 MMSL
000638 NDDF
004492 NDDF
1269092006 SNOMEDCT_US
129484001 SNOMEDCT_US
387068008 SNOMEDCT_US
412519000 SNOMEDCT_US
CHEMBL1201091 ChEMBL_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Terazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-1337 CAPSULE 1 mg ORAL ANDA 22 sections
Terazosin HUMAN PRESCRIPTION DRUG LABEL 1 0615-1338 CAPSULE 2 mg ORAL ANDA 25 sections
Terazosin HUMAN PRESCRIPTION DRUG LABEL 1 0615-1339 CAPSULE 5 mg ORAL ANDA 25 sections
Terazosin HUMAN PRESCRIPTION DRUG LABEL 1 10544-289 CAPSULE 10 mg ORAL ANDA 22 sections
Terazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 21695-812 CAPSULE 2 mg ORAL ANDA 24 sections
Terazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 21695-813 CAPSULE 5 mg ORAL ANDA 24 sections
terazosin HUMAN PRESCRIPTION DRUG LABEL 1 23155-735 CAPSULE 1 mg ORAL ANDA 20 sections
terazosin HUMAN PRESCRIPTION DRUG LABEL 1 23155-736 CAPSULE 2 mg ORAL ANDA 20 sections
terazosin HUMAN PRESCRIPTION DRUG LABEL 1 23155-737 CAPSULE 5 mg ORAL ANDA 20 sections
terazosin HUMAN PRESCRIPTION DRUG LABEL 1 23155-738 CAPSULE 10 mg ORAL ANDA 20 sections
Terazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 24689-792 CAPSULE 1 mg ORAL ANDA 25 sections
Terazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 24689-792 CAPSULE 1 mg ORAL ANDA 25 sections
Terazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 24689-792 CAPSULE 1 mg ORAL ANDA 25 sections
Terazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 24689-855 CAPSULE 2 mg ORAL ANDA 25 sections
Terazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 24689-855 CAPSULE 2 mg ORAL ANDA 25 sections
Terazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 24689-855 CAPSULE 2 mg ORAL ANDA 25 sections
Terazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 24689-882 CAPSULE 5 mg ORAL ANDA 25 sections
Terazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 24689-882 CAPSULE 5 mg ORAL ANDA 25 sections
Terazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 24689-882 CAPSULE 5 mg ORAL ANDA 25 sections
Terazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 24689-961 CAPSULE 10 mg ORAL ANDA 25 sections
Terazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 24689-961 CAPSULE 10 mg ORAL ANDA 25 sections
Terazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 24689-961 CAPSULE 10 mg ORAL ANDA 25 sections
Terazosin HUMAN PRESCRIPTION DRUG LABEL 1 33261-211 CAPSULE 1 mg ORAL ANDA 22 sections
Terazosin HUMAN PRESCRIPTION DRUG LABEL 1 33261-212 CAPSULE 2 mg ORAL ANDA 22 sections
Terazosin HUMAN PRESCRIPTION DRUG LABEL 1 33261-870 CAPSULE 10 mg ORAL ANDA 22 sections
Terazosin HUMAN PRESCRIPTION DRUG LABEL 1 42291-820 CAPSULE 1 mg ORAL ANDA 26 sections
Terazosin HUMAN PRESCRIPTION DRUG LABEL 1 42291-821 CAPSULE 2 mg ORAL ANDA 26 sections
Terazosin HUMAN PRESCRIPTION DRUG LABEL 1 42291-822 CAPSULE 5 mg ORAL ANDA 26 sections
Terazosin HUMAN PRESCRIPTION DRUG LABEL 1 42291-823 CAPSULE 10 mg ORAL ANDA 26 sections
TERAZOSIN HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 42549-666 CAPSULE 5 mg ORAL ANDA 24 sections